probucol has been researched along with Nephrotic Syndrome in 15 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Nephrotic Syndrome: A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a prospective, uncontrolled multicenter study, we have evaluated the effects of probucol on hyperlipidemia, proteinuria, and glomerular filtration rate (GFR) in hyperlipidemic children with persistent nephrotic syndrome." | 7.70 | Probucol for treatment of hyperlipidemia in persistent childhood nephrotic syndrome. Report of a prospective uncontrolled multicenter study. ( Fiehn, W; Kohl, B; Michalk, D; Minor, T; Müller-Wiefel, DE; Querfeld, U; Schärer, K, 1999) |
| "Hyperlipidemia associated with nephrotic syndrome was treated with probucol and the changes in plasma lipoprotein lipid concentration and urinary protein excretion were examined in puromycin aminonucleoside-induced nephrotic rats." | 7.68 | The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats. ( Hirano, T; Mamo, JC; Nagano, S; Sugisaki, T, 1991) |
| "We have evaluated the effect of the antihyperlipidemic agent probucol on hyperlipidemia in patients with nephrotic syndrome." | 7.67 | Effect of probucol on hyperlipidemia in patients with nephrotic syndrome. ( Asaka, M; Fujita, M; Iida, H; Izumino, K; Nishino, A; Sasayama, S, 1987) |
| " Recently, a new microemulsion formulation of CyA(Neoral) has been developed and used preferably because of a more stable bioavailability than an oily formulation(Sandimmun)." | 5.31 | [Effect of probucol on the blood concentration of cyclosporin A in patients with nephrotic syndrome: a case study with a microemulsion formulation (Neoral)]. ( Inui, K; Muso, E; Ono, T; Wakasugi, H; Yoshimoto, M, 2002) |
| "Nephrotic syndrome accompanies hyperlipidemia for which HMG-CoA reductase inhibitors are mainly used." | 5.31 | [Effect of probucol on the concentration of cyclosporin A in patients with nephrotic syndrome]. ( Aoki, M; Futami, T; Inui, K; Muso, E; Ono, T; Osawa, R; Wakasugi, H; Yoshimoto, M, 2001) |
| " The authors treated a 36-year-old woman with LPG and exhibiting a nephrotic syndrome using an intensive lipid-lowering therapy consisting of fenofibrate (300 mg), niceritrol (750 mg), ethyl-icosapentate (1,800 mg), and probucol (500 mg)." | 3.72 | Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy. ( Hotta, O; Ieiri, N; Taguma, Y, 2003) |
| "In a prospective, uncontrolled multicenter study, we have evaluated the effects of probucol on hyperlipidemia, proteinuria, and glomerular filtration rate (GFR) in hyperlipidemic children with persistent nephrotic syndrome." | 3.70 | Probucol for treatment of hyperlipidemia in persistent childhood nephrotic syndrome. Report of a prospective uncontrolled multicenter study. ( Fiehn, W; Kohl, B; Michalk, D; Minor, T; Müller-Wiefel, DE; Querfeld, U; Schärer, K, 1999) |
| "Hyperlipidemia associated with nephrotic syndrome was treated with probucol and the changes in plasma lipoprotein lipid concentration and urinary protein excretion were examined in puromycin aminonucleoside-induced nephrotic rats." | 3.68 | The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats. ( Hirano, T; Mamo, JC; Nagano, S; Sugisaki, T, 1991) |
| "We have evaluated the effect of the antihyperlipidemic agent probucol on hyperlipidemia in patients with nephrotic syndrome." | 3.67 | Effect of probucol on hyperlipidemia in patients with nephrotic syndrome. ( Asaka, M; Fujita, M; Iida, H; Izumino, K; Nishino, A; Sasayama, S, 1987) |
| " Recently, a new microemulsion formulation of CyA(Neoral) has been developed and used preferably because of a more stable bioavailability than an oily formulation(Sandimmun)." | 1.31 | [Effect of probucol on the blood concentration of cyclosporin A in patients with nephrotic syndrome: a case study with a microemulsion formulation (Neoral)]. ( Inui, K; Muso, E; Ono, T; Wakasugi, H; Yoshimoto, M, 2002) |
| "Nephrotic syndrome accompanies hyperlipidemia for which HMG-CoA reductase inhibitors are mainly used." | 1.31 | [Effect of probucol on the concentration of cyclosporin A in patients with nephrotic syndrome]. ( Aoki, M; Futami, T; Inui, K; Muso, E; Ono, T; Osawa, R; Wakasugi, H; Yoshimoto, M, 2001) |
| "Probucol treatment significantly reduced the lipid concentration in all major lipoproteins, significantly reduced proteinuria and increased plasma albumin concentration." | 1.28 | Treatment of hyperlipidemia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis. ( Hirano, T; Morohoshi, T, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 9 (60.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsunaga, A | 1 |
| Furuyama, M | 1 |
| Hashimoto, T | 1 |
| Toyoda, K | 1 |
| Ogino, D | 1 |
| Hayasaka, K | 1 |
| Ieiri, N | 1 |
| Hotta, O | 1 |
| Taguma, Y | 1 |
| Wakasugi, H | 2 |
| Yoshimoto, M | 2 |
| Ono, T | 2 |
| Muso, E | 2 |
| Inui, K | 2 |
| Magil, A | 1 |
| Drukker, A | 1 |
| Eddy, AA | 1 |
| Querfeld, U | 1 |
| Kohl, B | 1 |
| Fiehn, W | 1 |
| Minor, T | 1 |
| Michalk, D | 1 |
| Schärer, K | 1 |
| Müller-Wiefel, DE | 1 |
| Aoki, M | 1 |
| Osawa, R | 1 |
| Futami, T | 1 |
| Hirano, T | 3 |
| Morohoshi, T | 1 |
| Mamo, JC | 2 |
| Nagano, S | 1 |
| Sugisaki, T | 2 |
| D'Amico, G | 1 |
| Gentile, MG | 1 |
| Nakai, T | 1 |
| Matsuda, T | 1 |
| Takai, H | 1 |
| Maeda, H | 1 |
| Takahashi, S | 1 |
| Oida, K | 1 |
| Tamai, T | 1 |
| Miyaho, S | 1 |
| Morikawa, K | 1 |
| Kurota, M | 1 |
| Grundy, SM | 1 |
| Ohnami, K | 1 |
| Valeri, A | 1 |
| Gelfand, J | 1 |
| Blum, C | 1 |
| Appel, GB | 1 |
| Iida, H | 1 |
| Izumino, K | 1 |
| Asaka, M | 1 |
| Fujita, M | 1 |
| Nishino, A | 1 |
| Sasayama, S | 1 |
1 review available for probucol and Nephrotic Syndrome
| Article | Year |
|---|---|
Management of hyperlipidemia of kidney disease.
Topics: Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolem | 1990 |
2 trials available for probucol and Nephrotic Syndrome
| Article | Year |
|---|---|
Pharmacological and dietary treatment of lipid abnormalities in nephrotic patients.
Topics: Cholestyramine Resin; Colestipol; Food, Formulated; Gemfibrozil; Humans; Hyperlipidemias; Lipids; Lo | 1991 |
Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Colestipol; Female; Human | 1986 |
12 other studies available for probucol and Nephrotic Syndrome
| Article | Year |
|---|---|
Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Apoli | 2009 |
Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins E; Drug Combinations; Eicosapentaenoic Acid; Female | 2003 |
[Effect of probucol on the blood concentration of cyclosporin A in patients with nephrotic syndrome: a case study with a microemulsion formulation (Neoral)].
Topics: Aged; Anticholesteremic Agents; Cyclosporine; Drug Interactions; Drug Monitoring; Drug Therapy, Comb | 2002 |
Inhibition of progression of chronic puromycin aminonucleoside nephrosis by probucol, an antioxidant.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Chronic Disease; Disease Models, Animal; Disease | 1996 |
Failure of antioxidant therapy to attenuate interstitial disease in rats with reversible nephrotic syndrome.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Cholesterol; Collagen; Female; Fibronectins; Fibros | 1998 |
Probucol for treatment of hyperlipidemia in persistent childhood nephrotic syndrome. Report of a prospective uncontrolled multicenter study.
Topics: Adolescent; Adult; Anticholesteremic Agents; Child; Child, Preschool; Electrocardiography; Glomerula | 1999 |
[Effect of probucol on the concentration of cyclosporin A in patients with nephrotic syndrome].
Topics: Adult; Aged; Anticholesteremic Agents; Cyclosporine; Drug Interactions; Drug Therapy, Combination; F | 2001 |
Treatment of hyperlipidemia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis.
Topics: Animals; Glomerulosclerosis, Focal Segmental; Hyperlipidemias; Male; Nephrotic Syndrome; Probucol; P | 1992 |
The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats.
Topics: Animals; Hyperlipidemias; Hyperlipoproteinemias; Kidney; Male; Nephrotic Syndrome; Organ Size; Probu | 1991 |
[A case of familial hypercholesterolemia associated with nephrotic syndrome].
Topics: Cholestyramine Resin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipoproteinem | 1990 |
Treatment of hyperlipidemia with probucol reduces proteinuria in puromycin aminonucleoside-induced nephrotic rats.
Topics: Animals; Hyperlipidemias; Male; Nephrotic Syndrome; Phenols; Probucol; Proteinuria; Puromycin Aminon | 1990 |
Effect of probucol on hyperlipidemia in patients with nephrotic syndrome.
Topics: Adult; Cholesterol; Female; Humans; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, LDL; Male; Mid | 1987 |